LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Edwards Lifesciences Corp

Suletud

SektorTervishoid

85.98 3.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

85.43

Max

86.01

Põhinäitajad

By Trading Economics

Sissetulek

290M

381M

Müük

79M

1.6B

P/E

Sektori keskmine

44.059

49.701

Aktsiakasum

0.78

Kasumimarginaal

23.092

Töötajad

16,000

EBITDA

382M

515M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+14.08% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

140M

47B

Eelmine avamishind

82.69

Eelmine sulgemishind

85.98

Uudiste sentiment

By Acuity

49%

51%

143 / 345 Pingereas Healthcare

Edwards Lifesciences Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. jaan 2026, 00:16 UTC

Omandamised, ülevõtmised, äriostud

Edwards Lifesciences Drops Merger With JenaValve

6. aug 2025, 18:44 UTC

Omandamised, ülevõtmised, äriostud

FTC Files Lawsuit to Block Edwards Lifesciences' Purchase of JenaValve Technology

Võrdlus sarnastega

Hinnamuutus

Edwards Lifesciences Corp Prognoos

Hinnasiht

By TipRanks

14.08% tõus

12 kuu keskmine prognoos

Keskmine 97.86 USD  14.08%

Kõrge 110 USD

Madal 85 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Edwards Lifesciences Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

15

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

143 / 345 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat